Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 14/20 | 0.68 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | DRD4 | P21917 | 2/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | GLA | P06280 | 4/20 | 0.37 |
| ▸ | GAA | P10253 | 4/20 | 0.37 |
| ▸ | HPGD | P15428 | 4/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 2/20 | 0.36 |
| ▸ | CASP7 | P55210 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16197847 | 0.81 | ERN1 (1.00) | ERN1DRD2DRD4DRD3KDM4E | |
| SCHEMBL17601909 | 0.77 | ERN1 (1.00) | ERN1DRD2DRD4DRD3 | |
| SCHEMBL17615422 | 0.76 | ERN1 (0.82) | ERN1DRD2DRD4DRD3KDM4E | |
| SCHEMBL17601922 | 0.75 | ERN1 (1.00) | ERN1KDM4EALDH1A1GLAGAA | |
| SCHEMBL17601889 | 0.74 | ERN1 (1.00) | ERN1DRD2DRD4DRD3KDM4E | |
| SCHEMBL17601914 | 0.72 | ERN1 (1.00) | ERN1KDM4EALDH1A1GLAGAA | |
| SCHEMBL17615426 | 0.72 | ERN1 (0.82) | ERN1KDM4EALDH1A1GLAGAA | |
| SCHEMBL16197814 | 0.70 | ERN1 (1.00) | ERN1KDM4EALDH1A1GLAGAA | |
| SCHEMBL17615419 | 0.69 | ERN1 (0.70) | ERN1KDM4EALDH1A1GLAGAA | |
| SCHEMBL17615420 | 0.68 | ERN1 (0.68) | ERN1KDM4EALDH1A1GLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10323013-B2 | Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2019-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10323013-B2 | Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof | XBP1, ERN1, SREBF1 | ERN1 2/4885DRD2 4261/4885DRD4 4683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.